Immunostimulants drugs for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
CAPSID NCT04433910		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	53/52	inconclusive	inconclusive 58 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
CP-COVID-19 NCT04332835		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	49/51	inconclusive	inconclusive 12 % increase in viral clearance (PE) with a moderate degree of certainty due to some concern in risk of bias
O’Donnell NCT04359810		RCT	convalescent plasma treatment	placebo	COVID-19 severe or critically	low	150/73	inconclusive	inconclusive 38 % increase in clinical improvement (28-day) (PE) with a high degree of certainty due to low risk of bias
Pouladzadeh IRCT20200310046736N1		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	31/31	suggested	suggested 6.3-fold increase in clinical improvement,clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
Raman CTRI/2020/06/026222		RCT	immunoglobulin therapy	standard of care	COVID-19 severe or critically	some concern	50/50	suggested	suggested 35.4-fold increase in viral clearance ,viral clearance by day 14 with a moderate degree of certainty due to some concern in risk of bias
RECOVER EudCT 2020-001632-10		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	low	43/47	inconclusive
REMAP-CAP (plasma) NCT02735707		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	low	1095/916	safety concern	statistically significant 1.3-fold increase in serious adverse events with a high degree of certainty due to low risk of bias
Sekine (PLACOVID) NCT04547660		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	80/80	inconclusive	inconclusive 6 % decrease in clinical improvement,clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
AlQahtani NCT04356534		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	20/20	inconclusive	inconclusive 33 % decrease in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
Gharebaghi IRCT20200501047259N1		RCT	immunoglobulin therapy	placebo	COVID-19 severe or critically	NA	30/29	suggested	suggested 100 % decrease in deaths,death D28
ILBS-COVID-02 (Bajpai M) NCT04346446		RCT	convalescent plasma treatment	placebo	COVID-19 severe or critically	high	14/15	inconclusive	inconclusive 74 % decrease in off oxygenation (PE) but with a low degree of certainty due to high risk of bias
Li ChiCTR2000029757		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	52/51	inconclusive	inconclusive 40 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
PICP19 (Ray) CTRI/2020/05/025209		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically
bias due to deviations from intended interventions	some concern
bias due to missing outcome data	low
bias in measurement of the primary outcome	low
bias in selection of the reported result	high

" >high
40/40

inconclusive 33 % decrease in deaths,death D28 (PE) but with a low degree of certainty due to high risk of bias

NCT04344535 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or critically
228/106

inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias

RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or critically
21/28

IRCT20151227025726N2 RCTimmunoglobulin therapy standard of careCOVID-19 severe or critically
52/32

inconclusive 10 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
inconclusive 49 % increase in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
inconclusive 44 % decrease in ICU admission (PE) with a moderate degree of certainty due to some concern in risk of bias

4 studies excluded by filtering options (0 RCT / 4 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis